Showing results (191-200 of 280) with videos related to

Sort By:
Pageof 28
BMJ Open|September 14, 2022
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trialDaniel J George, David R Spigel, Lucio N Gordan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)Andrew B Nixon, Susan Halabi, Yingmiao Liu, et al.
Urologic Oncology|March 15, 2011
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancerYoung E Whang, Andrew J Armstrong, W Kimryn Rathmell, et al.
The Journal of Urology|November 18, 2011
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate CenterSuzanne Biehn Stewart, Lionel L Bañez, Cary N Robertson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinomaBrian I Rini, M Dror Michaelson, Jonathan E Rosenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphomaLeigh Ellis, Yan Pan, Gordon K Smyth, et al.
The Prostate|March 14, 2022
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancerTian Zhang, Julie Kephart, Elizabeth Bronson, et al.
Biomarker Research|February 19, 2021
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancerTian Zhang, Anika Agarwal, R Garland Almquist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2018
Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic AnalysisDaniel J George, Jean-Francois Martini, Michael Staehler, et al.
Eclinicalmedicine|May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerCelestia S Higano, Daniel J George, Neal D Shore, et al.
Pageof 28